SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neopath (NPTH)
NPTH 0.0006000.0%Mar 7 3:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sigmund who wrote (77)12/16/1997 12:33:00 AM
From: Jim Armstrong  Read Replies (1) of 178
 
The stock price of NPTH has always seemed to be inclined to bob up and down a bit, and be somewhat to the market's feelings about tech stocks in general. Having said that, I also gotta tell you that I am pretty much a novice at this type of investing and this was one of my early acquisitions. I bought it initially because I knew something about the company via knowing an excellent technologist that went to be a part of the company. A little later, I got to meet some of the key folks, and I'm just gonna stick it out, at least until the FDA meeting on Jan 28. [I also increased my position a little]. That primary screener approval is critical. I think they have a pretty good shot this go around. They have the approval in Japan. I am willing to believe that they have really concentrated on the quality of their submittal following the non-approval in their first run at FDA primary screener approval.

I just don't know the market or investor behaviors well enough to speculate on those. JimA
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News